PDCD1 and neoplasm: (43), in their clinical trials, used personalized tumor neoantigen vaccine (NEO-PV-01) and PD-1 inhibitor in the treatment of three kinds of high TMB, metastatic tumors (NSCLC, advanced bladder and melanoma cancer) for the first time, and the scTCR-seq analysis revealed the dynamic changes in the clonal type of tumor neoantigen vaccine-specific T cells, and accurately detailed characterized the T cell response.